vs
CareDx, Inc.（CDNA）与Natera, Inc.（NTRA）财务数据对比。点击上方公司名可切换其他公司
Natera, Inc.的季度营收约是CareDx, Inc.的6.1倍（$665.5M vs $108.4M）。Natera, Inc.净利率更高（7.1% vs -3.8%，领先10.9%）。Natera, Inc.同比增速更快（39.8% vs 25.2%）。过去两年Natera, Inc.的营收复合增速更高（34.5% vs 22.7%）
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
Natera是总部位于美国得克萨斯州奥斯汀的临床基因检测企业，主打无创游离DNA（cfDNA）检测技术，业务覆盖女性健康、肿瘤及器官健康三大核心赛道。其自研专利技术结合前沿分子生物学手段与生物信息学工具矩阵，可实现单管血液样本中低至单个分子级别的高灵敏度检测。
CDNA vs NTRA — 直观对比
营收规模更大
NTRA
是对方的6.1倍
$108.4M
营收增速更快
NTRA
高出14.6%
25.2%
净利率更高
NTRA
高出10.9%
-3.8%
两年增速更快
NTRA
近两年复合增速
22.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $108.4M | $665.5M |
| 净利润 | $-4.1M | $47.3M |
| 毛利率 | — | — |
| 营业利润率 | -5.6% | -3.4% |
| 净利率 | -3.8% | 7.1% |
| 营收同比 | 25.2% | 39.8% |
| 净利润同比 | -104.7% | 187.9% |
| 每股收益（稀释后） | $-0.08 | $0.36 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDNANTRA
| Q4 25 | $108.4M | $665.5M | ||
| Q3 25 | $100.1M | $592.2M | ||
| Q2 25 | $86.7M | $546.6M | ||
| Q1 25 | $84.7M | $501.8M | ||
| Q4 24 | $86.6M | $476.1M | ||
| Q3 24 | $82.9M | $439.8M | ||
| Q2 24 | $92.3M | $413.4M | ||
| Q1 24 | $72.0M | $367.7M |
净利润CDNANTRA
| Q4 25 | $-4.1M | $47.3M | ||
| Q3 25 | $1.7M | $-87.5M | ||
| Q2 25 | $-8.6M | $-100.9M | ||
| Q1 25 | $-10.4M | $-66.9M | ||
| Q4 24 | $87.7M | $-53.8M | ||
| Q3 24 | $-10.6M | $-31.6M | ||
| Q2 24 | $-4.6M | $-37.5M | ||
| Q1 24 | $-19.9M | $-67.6M |
营业利润率CDNANTRA
| Q4 25 | -5.6% | -3.4% | ||
| Q3 25 | -0.2% | -16.5% | ||
| Q2 25 | -12.8% | -20.2% | ||
| Q1 25 | -15.8% | -15.8% | ||
| Q4 24 | 97.5% | -13.6% | ||
| Q3 24 | -16.6% | -8.9% | ||
| Q2 24 | -7.9% | -10.6% | ||
| Q1 24 | -31.3% | -20.2% |
净利率CDNANTRA
| Q4 25 | -3.8% | 7.1% | ||
| Q3 25 | 1.7% | -14.8% | ||
| Q2 25 | -9.9% | -18.5% | ||
| Q1 25 | -12.2% | -13.3% | ||
| Q4 24 | 101.3% | -11.3% | ||
| Q3 24 | -12.8% | -7.2% | ||
| Q2 24 | -5.0% | -9.1% | ||
| Q1 24 | -27.6% | -18.4% |
每股收益（稀释后）CDNANTRA
| Q4 25 | $-0.08 | $0.36 | ||
| Q3 25 | $0.03 | $-0.64 | ||
| Q2 25 | $-0.16 | $-0.74 | ||
| Q1 25 | $-0.19 | $-0.50 | ||
| Q4 24 | $1.60 | $-0.41 | ||
| Q3 24 | $-0.20 | $-0.26 | ||
| Q2 24 | $-0.09 | $-0.30 | ||
| Q1 24 | $-0.38 | $-0.56 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $177.2M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $303.1M | $1.7B |
| 总资产 | $413.2M | $2.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CDNANTRA
| Q4 25 | $177.2M | — | ||
| Q3 25 | $194.2M | $1.0M | ||
| Q2 25 | $186.3M | $16.0M | ||
| Q1 25 | $230.9M | $17.8M | ||
| Q4 24 | $260.7M | $22.7M | ||
| Q3 24 | $240.9M | $29.5M | ||
| Q2 24 | $228.9M | $90.3M | ||
| Q1 24 | $215.9M | $69.1M |
总债务CDNANTRA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | — | — |
股东权益CDNANTRA
| Q4 25 | $303.1M | $1.7B | ||
| Q3 25 | $311.1M | $1.3B | ||
| Q2 25 | $327.4M | $1.2B | ||
| Q1 25 | $379.3M | $1.2B | ||
| Q4 24 | $378.4M | $1.2B | ||
| Q3 24 | $273.2M | $878.5M | ||
| Q2 24 | $264.7M | $836.5M | ||
| Q1 24 | $256.2M | $794.1M |
总资产CDNANTRA
| Q4 25 | $413.2M | $2.4B | ||
| Q3 25 | $432.3M | $1.8B | ||
| Q2 25 | $444.3M | $1.8B | ||
| Q1 25 | $489.6M | $1.7B | ||
| Q4 24 | $491.1M | $1.7B | ||
| Q3 24 | $477.0M | $1.6B | ||
| Q2 24 | $466.8M | $1.5B | ||
| Q1 24 | $452.4M | $1.5B |
负债/权益比CDNANTRA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $21.4M | $73.9M |
| 自由现金流经营现金流 - 资本支出 | — | $37.8M |
| 自由现金流率自由现金流/营收 | — | 5.7% |
| 资本支出强度资本支出/营收 | — | 5.4% |
| 现金转化率经营现金流/净利润 | — | 1.56× |
| 过去12个月自由现金流最近4个季度 | — | $109.1M |
8季度趋势，按日历期对齐
经营现金流CDNANTRA
| Q4 25 | $21.4M | $73.9M | ||
| Q3 25 | $37.4M | $59.4M | ||
| Q2 25 | $9.9M | $37.6M | ||
| Q1 25 | $-26.6M | $44.5M | ||
| Q4 24 | $21.9M | $52.9M | ||
| Q3 24 | $12.5M | $51.8M | ||
| Q2 24 | $18.9M | $4.0M | ||
| Q1 24 | $-15.3M | $27.0M |
自由现金流CDNANTRA
| Q4 25 | — | $37.8M | ||
| Q3 25 | — | $37.0M | ||
| Q2 25 | — | $11.7M | ||
| Q1 25 | — | $22.6M | ||
| Q4 24 | — | $34.8M | ||
| Q3 24 | — | $35.5M | ||
| Q2 24 | — | $-7.7M | ||
| Q1 24 | — | $6.7M |
自由现金流率CDNANTRA
| Q4 25 | — | 5.7% | ||
| Q3 25 | — | 6.2% | ||
| Q2 25 | — | 2.1% | ||
| Q1 25 | — | 4.5% | ||
| Q4 24 | — | 7.3% | ||
| Q3 24 | — | 8.1% | ||
| Q2 24 | — | -1.9% | ||
| Q1 24 | — | 1.8% |
资本支出强度CDNANTRA
| Q4 25 | — | 5.4% | ||
| Q3 25 | — | 3.8% | ||
| Q2 25 | — | 4.7% | ||
| Q1 25 | — | 4.3% | ||
| Q4 24 | — | 3.8% | ||
| Q3 24 | — | 3.7% | ||
| Q2 24 | — | 2.8% | ||
| Q1 24 | — | 5.5% |
现金转化率CDNANTRA
| Q4 25 | — | 1.56× | ||
| Q3 25 | 22.30× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDNA
| Services | $78.4M | 72% |
| Patient And Digital Solutions | $16.8M | 15% |
| Products | $13.3M | 12% |
NTRA
暂无分部数据
